Update on the ECG component of the CiPA initiative

Area of Science:

• Cardiovascular pharmacology
• Computational toxicology
• Clinical electrophysiology

Background:

• Traditional drug safety assessments focus on hERG block and QT prolongation.
• The Comprehensive in vitro Proarrhythmia Assay (CiPA) offers a new paradigm using multiple ion channel data.
• In silico modeling and clinical ECG data integration are central to CiPA.

Purpose of the Study:

• To review the electrocardiogram (ECG) component of the CiPA initiative.
• To describe ECG methods used in the CiPA ECG validation clinical study.
• To highlight the role of ECG biomarkers in assessing drug-induced arrhythmia risk.

Main Methods:

• Utilizing in vitro data on drug effects on multiple cardiac ion channels.
• Employing an in silico model of the human cardiomyocyte for drug risk classification.
• Analyzing early phase 1 ECG data to correlate with in vitro findings.
• Evaluating 12 ECG biomarkers, focusing on the heart rate corrected J-Tpeak interval (J-Tpeakc).

Main Results:

• The J-Tpeakc interval was identified as the optimal biomarker for detecting late sodium current block with hERG block.
• Predominant hERG blockers prolonged both QTc and J-Tpeakc.
• Balanced ion channel blockers (affecting hERG, late sodium, and/or calcium currents) prolonged QTc but not J-Tpeakc.

Conclusions:

• CiPA provides a more comprehensive assessment of proarrhythmic potential beyond traditional metrics.
• The J-Tpeakc interval is a valuable ECG biomarker for differentiating drug-induced ion channel effects.
• Integrating in vitro, in silico, and clinical ECG data enhances drug safety evaluation for torsade de pointes risk.